Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Douglas A MataJessica K LeeVignesh ShanmugamChelsea B MarcusAlexa B SchrockErik A WilliamsLauren L RitterhouseRichard A HickmanTyler JanovitzNimesh R PatelBenjamin R KrogerJeffrey S RossKamran M MirzaGeoffrey R OxnardJo-Anne VergilioJulia A ElvinJamal K BenhamidaBrennan DeckerMina L XuPublished in: Histopathology (2024)
These data demonstrate that LBx can detect relevant genomic alterations across HNs, including at low clonal fractions, suggesting a potential clinical utility for identifying residual or emerging therapy-resistant clones that may be undetectable in site-specific tissue biopsies.
Keyphrases
- ultrasound guided
- circulating tumor
- computed tomography
- image quality
- electronic health record
- bone marrow
- dual energy
- dendritic cells
- cell free
- contrast enhanced
- single molecule
- acute myeloid leukemia
- ionic liquid
- copy number
- fine needle aspiration
- big data
- stem cells
- positron emission tomography
- magnetic resonance
- magnetic resonance imaging
- nucleic acid
- immune response
- data analysis
- artificial intelligence
- genome wide
- cell therapy